Proteomic profiling of potential molecular targets of methyl-selenium compounds in the transgenic adenocarcinoma of mouse prostate model

Cancer Prevention Research

Volumn 3, Issue 8, 2010, Pages 994-1006

  Zhang, Jinhui ^a   Wang, Lei ^a   Anderson, Lorraine B ^a   Witthuhn, Bruce ^a   Xu, Yanji ^a   Lü, Junxuan ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CALPONIN; GLUCOSE REGULATED PROTEIN 78; GLUTATHIONE TRANSFERASE M1; METHYL GROUP; METHYLSELENINIC ACID; METHYLSELENOCYSTEINE; SELENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROTECTION; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION PROFILING; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; STROMA CELL; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; TREATMENT DURATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BIOMARKERS, PHARMACOLOGICAL; CYSTEINE; DISEASE MODELS, ANIMAL; MALE; METABOLOME; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; ORGANOSELENIUM COMPOUNDS; PROSTATIC NEOPLASMS; PROTEOMICS; SELENIUM COMPOUNDS; SELENOMETHIONINE; TUMOR MARKERS, BIOLOGICAL;

EID: 77955449641     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0261     Document Type: Article

References (49)

1. Klein EA. Can prostate cancer be prevented? Nat Clin Pract Urol 2005;2:24-31.
2. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81:730-4.
3. Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004;96:696-703.
4. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001; 166:2034-8.
5. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301: 39-51.
6. El-Bayoumy K. The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr Cancer 2009;61:285-6.
7. McCormick DL, Rao KV. Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat. Eur Urol 1999;35:464-7.
8. Corcoran NM, Najdovska M, Costello AJ. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 2004;171:907-10.
9. Li GX, Lee HJ, Wang Z, et al. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008;29:1005-12.
10. Wang L, Bonorden MJ, Li GX, et al. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res 2009;2:484-95.
11. Lu J, Jiang C. Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal 2005;7:1715-27.
12. Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman CA, Jr. Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology 2008;71:854-7.
13. Han DK, Eng J, Zhou H, Aebersold R. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat Biotechnol 2001;19:946-51.
14. Stewart II, Thomson T, Figeys D. 18O labeling: a tool for proteomics. Rapid Commun Mass Spectrom 2001;15:2456-65.
15. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004;3:1154-69.
16. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
17. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
18. Chiaverotti T, Couto SS, Donjacour A, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-46.
19. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000;42:274-9.
20. Yeh IT, Reddick RL, Kumar AP. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Prostate 2009;69:755-60.
21. Shilov IV, Seymour SL, Patel AA, et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 2007;6:1638-55.
22. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001;61:3062-70.
23. Kassie F, Anderson LB, Scherber R, et al. Indole-3-carbinol inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo(a) pyrene-induced lung tumorigenesis in A/J mice and modulates carcinogen-induced alterations in protein levels. Cancer Res 2007; 67:6502-11.
24. Pace AJ, Lee E, Athirakul K, Coffman TM, O'Brien DA, Koller BH. Failure of spermatogenesis in mouse lines deficient in the Na(+)-K (+)-2Cl(-) cotransporter. J Clin Invest 2000;105:441-50.
25. Balani P, Boulaire J, Zhao Y, Zeng J, Lin J, Wang S. High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment. Mol Ther 2009;17:1003-11.
26. Johnson MA, Hernandez I, Wei Y, Greenberg N. Isolation and characterization of mouse probasin: an androgen-regulated protein specifically expressed in the differentiated prostate. Prostate 2000;43: 255-62.
27. Haram KM, Peltier HJ, Lu B, et al. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Prostate 2008;68:1517-30.
28. Fujimoto N, Akimoto Y, Suzuki T, Kitamura S, Ohta S. Identification of prostatic-secreted proteins in mice by mass spectrometric analysis and evaluation of lobe-specific and androgen-dependent mRNA expression. J Endocrinol 2006;190:793-803.
29. Ruddat VC, Whitman S, Klein RD, Fischer SM, Holman TR. Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma. Prostate 2005;64:128-38.
30. Birckbichler PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV, Hemstreet GP III. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 2000;89:412-23.
31. Setiady YY, Ohno K, Samy ET, et al. Physiologic self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+ CD25+ regulatory T cells. Blood 2006;107:1056-62.
32. Fujimoto N, Suzuki T, Ohta S, Kitamura S. Identification of rat prostatic secreted proteins using mass spectrometric analysis and androgen-dependent mRNA expression. J Androl 2009;30:669-78.
33. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005;65:4218-27.
34. Agalliu I, Lin DW, Salinas CA, Feng Z, Stanford JL. Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate 2006;66:1535-41.
35. Sivonova M, Waczulikova I, Dobrota D, et al. Polymorphisms of glutathione-S-transferase M1, T1, P1 and the risk of prostate cancer: a case-control study. J Exp Clin Cancer Res 2009;28:32.
36. Garbis SD, Tyritzis SI, Roumeliotis T, et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008;7:3146-58.
37. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8:2912-23.
38. Ayala G, Tuxhorn JA, Wheeler TM, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003;9:4792-801.
39. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 2008;72: 205-13.
40. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002;50:54-63.
41. Assinder SJ, Stanton JA, Prasad PD. Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 2009;41: 482-6.
42. Koochekpour S, Lee TJ, Wang R, et al. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Prostate 2007;67:178-89.
43. Koochekpour S, Zhuang YJ, Beroukhim R, et al. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 2005;44:351-64.
44. Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004;64:19-22.
45. Cho SD, Jiang C, Malewicz B, et al. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 2004;3:605-11.
46. Tang Y, Wang L, Goloubeva O, Khan MA, Zhang B, Hussain A. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy. Clin Cancer Res 2008;14:2936-43.
47. Gao P, Sun X, Chen X, et al. Secretable chaperone Grp170 enhances therapeutic activity of a novel tumor suppressor, mda-7/IL-24. Cancer Res 2008;68:3890-8.
48. Zu K, Bihani T, Lin A, Park YM, Mori K, Ip C. Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 2006;25:546-54.
49. Zhang J, Wang L, Xu Y, Lu J. Analysis of global protein expression in murine prostate modulated by second-generation selenium compounds using LC-MS/MS coupled with amine-specific isobaric tagging (iTRAQ). Proc AACR 2009;50:2973.